EASTONBIOPHARMACEUTICALS(SH:688513)2020-10-26 16:00Financial Performance - Net profit attributable to shareholders increased by 31.53% to CNY 124,861,472.73 year-on-year[18]. - The company reported a net profit attributable to shareholders of RMB 124,861,472.73, an increase of 31.53% compared to RMB 94,929,397.80 from the previous year, driven by increased sales of Fumaric Acid Bisoprolol tablets and new product launches[37]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 93,521,317.36, reflecting a significant increase of 67.61% from RMB 55,796,130.69 in the same period last year[37]. - The net profit for Q3 2020 was CNY 38,784,682.93, a significant increase compared to CNY 15,728,634.62 in Q3 2019, representing a growth of approximately 146.5%[63]. - The company reported a net profit margin improvement, with net profit for the first three quarters of 2020 at approximately ¥335.29 million, compared to ¥212.11 million in the same period of 2019, an increase of about 58%[56]. Revenue and Income - Operating income decreased by 0.80% to CNY 672,755,703.53 compared to the same period last year[18]. - Total revenue for Q3 2020 was approximately ¥237.80 million, an increase from ¥202.87 million in Q3 2019, representing a growth of about 17.2%[59]. - The total revenue for the first three quarters of 2020 reached CNY 386,212,718.99, up from CNY 296,992,153.82 in the same period of 2019, indicating a year-over-year increase of about 30%[64]. Assets and Liabilities - Total assets increased by 144.00% to CNY 2,408,513,827.47 compared to the end of the previous year[18]. - The total assets as of the reporting date were approximately ¥2.05 billion, significantly up from ¥644.66 million in the previous year, marking an increase of approximately 218.5%[56]. - The total liabilities increased to ¥362,750,141.17 from ¥289,637,532.71, marking an increase of about 25.2%[49]. - The company's total liabilities amounted to RMB 61,231,914.85, indicating a manageable debt level[93]. Cash Flow - Net cash flow from operating activities decreased by 45.18% to CNY 75,402,330.31 year-to-date[18]. - Cash flow from operating activities generated a net amount of 75,402,330.31, down from 137,534,099.40 in the previous year[73]. - Cash inflow from operating activities totaled 745,953,906.44, a decrease from 794,969,214.53 year-over-year[73]. - Cash flow from financing activities generated a net inflow of 1,265,454,261.20, compared to a net outflow of 18,553,152.00 in the previous year[75]. Shareholder Information - The total number of shareholders reached 13,591 at the end of the reporting period[27]. - The largest shareholder, Wang Ying, holds 41,900,000 shares, representing 34.89% of the total shares[27]. - Basic and diluted earnings per share increased by 27.62% to CNY 1.34[21]. - Basic and diluted earnings per share were both 0.50, up from 0.26 in the same period last year[69]. Research and Development - R&D expenses accounted for 16.29% of operating income, a decrease of 1.01 percentage points compared to the previous year[21]. - Research and development expenses for Q3 2020 amounted to approximately ¥43.74 million, compared to ¥41.49 million in Q3 2019, reflecting an increase of about 5.4%[59]. - Research and development expenses for Q3 2020 were CNY 32,086,388.02, a decrease from CNY 37,215,250.94 in Q3 2019, showing a reduction of about 13.3%[64]. Inventory and Construction - The company’s inventory increased to RMB 81,512,310.85, a rise of 34.93% from RMB 60,412,899.64, attributed to increased production stockpiling[32]. - The company’s construction in progress increased to RMB 299,440,590.88, a rise of 179.31% from RMB 107,205,948.73, reflecting increased investment in IPO projects[32]. Government Subsidies and Non-Recurring Items - Government subsidies recognized in the current period amounted to CNY 10,225,144.99[19]. - Non-recurring gains and losses totaled CNY 9,674,378.27 year-to-date[26].